Adaptive Biotechnologies: Current Moat Is Strong, But Value Rides On Long-Term Innovation (Rating Upgrade)

2025-10-06 13:29:43 ET

Introduction

My last look at Adaptive Biotechnologies ( ADPT ) was in September 2024. The company was amid a post-pandemic transition. As revenues from its Immune Medicine ((IM)) segment, which included a COVID test product, were declining, Adaptive's Minimal Residual Disease ((MRD)) segment was beginning to pick up steam. However, I expressed some long-term concerns, such as MRD segment competition and Adaptive's R&D cost cuts, which could limit innovation in a market that demands it....

Read the full article on Seeking Alpha

For further details see: